Sam Fazeli

So you've got my mind racing here.

I've got so many questions, which of course we can't even finish our session if we just stayed on this.

But let me ask you a question.

In the seven years, the diamond in the rough, there are a lot of situations where somebody comes with an idea that may be a bit too early to be meaningful or biology changes five years down the road.

It doesn't change.

It gets more detailed.

Have you had the situation yet where you've gone back and said, oh, you know that company we said no to five years ago, that science?

Actually, it makes sense now.

Has that happened yet?

Or do you expect it to happen?

I think you're the only person who's put a positive spin on that because most people put a negative spin on it saying you want to be in biotech you've got to be in the Boston cluster or the San Francisco cluster because everything is there and everybody's there all the expertise is there.

I mean that makes some sense but I think you're the first person who's actually put a positive spin on the fact that Europe is for want of a better phrase fragmented because it's different countries essentially despite the European Union

is actually an element of it that's positive, but you need to be able to leverage that, which is what I think you're talking about.

Antoine, we've talked for half an hour.

It feels like five minutes, but that's normal.

I mean, I remember this sensation.

Let's just finish on this by asking you, where have you been surprised by the application of AI in the world of drug development and medicine?

And where have you been disappointed?

Just a couple, if I'm just putting you on the spot now, because that wasn't one of my questions.

Let's talk about the current sentiment and sector views, etc.